08 October 2019

Nick Morrell is awarded the 2019 ERS Lifetime Achievement in PAH


PVRI Board member Professor Nicholas Morrell, University of Cambridge, UK, received the 2019 ERS Lifetime Achievement Award in Pulmonary Arterial Hypertension. 

This award recognises an investigator whose research has had substantial impact and, who over an extended period of time, has advanced the knowledge and research in the field of pulmonary arterial hypertension (PAH). 

During the ERS International Congress held in September in Madrid, Spain, Nick received the 2019 ERS Lifetime Achievement Award in Pulmonary Arterial Hypertension. His research includes the use of mouse genetic models, humans and mouse cells and tissues, including progenitor cells and induce pluripotent stem cells, as well as experimental medicine studies in patients with PAH. 

Nick, who is currently co- Editor-in-Chief of the PVRI flagship journal Pulmonary Circulation, co-founded MorphogenX in 2015, a University of Cambridge spin-out company to develop bone morphogenetic proteins as a potential new treatment for PAH. He is the Research Director of the Pulmonary Vascular Diseases Unit at Royal Papworth Hospital, Cambridge, a national referral centre for patients with PAH. He leads the UK National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension and the International Consortium for Genetic Studies in PAH. He is the Director of the Cambridge Heart and Lung Research Institute.

He is a UK National Institute of Health Research Senior Investigator and was elected to the Fellowship of the Academy of Medical Sciences in 2011. He has served on the Scientific Steering Committee of the World Symposium on Pulmonary Hypertension, chairing the Genetics and Genomics Task Force. 

On receiving this prestigious award, Nick said:

I am honoured and delighted to receive this Lifetime Achievement Award from the European Respiratory Society for our research in the PAH field. This award recognises the efforts of our research group and collaborators over many years, as well as my mentors and, of course, the support of my family. I always like to think that our most exciting research breakthroughs are still to come. We have a lot of work to do to develop curative treatments for PAH, so I don’t plan on retiring from the field just yet!
Professor Nick Morrell, University of Cambridge, UK

Comments (1)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI